STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery. It makes lenses used across the world in corrective or refractive surgery, and makes lenses for use in surgery that treats cataracts. Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). As of December 30, 2016, it sold its products in more than 60 countries, with direct distribution in the United States, Canada, Japan and Spain, and independent distribution in the remainder of the world.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: Health Care Supplies
- Symbol: NASDAQ:STAA
- CUSIP: 85231230
- Web: www.staar.com
Capitalization:- Market Cap: $448.09 million
- Outstanding Shares: 41,108,000
Average Prices:- 50 Day Moving Avg: $11.51
- 200 Day Moving Avg: $10.28
- 52 Week Range: $7.45 - $12.35
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 57.37
- P/E Growth: -3.95
Sales & Book Value:- Annual Revenue: $84.48 million
- Price / Sales: 5.30
- Book Value: $0.93 per share
- Price / Book: 11.72
Profitability:- EBIDTA: ($672,999.00)
- Net Margins: -6.06%
- Return on Equity: -8.69%
- Return on Assets: -5.03%
Debt:- Debt-to-Equity Ratio: 0.03%
- Current Ratio: 2.52%
- Quick Ratio: 1.81%
Misc:- Average Volume: 88,398 shs.
- Beta: 1.21
- Short Ratio: 31.08
Frequently Asked Questions for STAAR Surgical Company (NASDAQ:STAA)
What is STAAR Surgical Company's stock symbol?
STAAR Surgical Company trades on the NASDAQ under the ticker symbol "STAA."
How were STAAR Surgical Company's earnings last quarter?
STAAR Surgical Company (NASDAQ:STAA) posted its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.05) by $0.04. The company earned $21.90 million during the quarter, compared to analyst estimates of $22.15 million. STAAR Surgical Company had a negative net margin of 6.06% and a negative return on equity of 8.69%. The business's quarterly revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.02) earnings per share. View STAAR Surgical Company's Earnings History.
When will STAAR Surgical Company make its next earnings announcement?
Where is STAAR Surgical Company's stock going? Where will STAAR Surgical Company's stock price be in 2017?
2 brokers have issued 1-year price objectives for STAAR Surgical Company's stock. Their forecasts range from $11.00 to $13.00. On average, they expect STAAR Surgical Company's stock price to reach $12.00 in the next year. View Analyst Ratings for STAAR Surgical Company.
Who are some of STAAR Surgical Company's key competitors?
Some companies that are related to STAAR Surgical Company include Orthofix International N.V. (OFIX), Intersect ENT (XENT), AtriCure (ATRC), CryoLife (CRY), Landauer (LDR), Meridian Bioscience (VIVO), Invacare Corporation (IVC), Consort Medical plc (CSRT), Antares Pharma (ATRS), Exactech (EXAC), Sientra (SIEN), Utah Medical Products (UTMD), Transenterix (TRXC), Transenterix (TRXC), Ocular Therapeutix (OCUL), T2 Biosystems (TTOO), SeaSpine Holdings Corporation (SPNE) and Bioquell plc (BQE).
Who are STAAR Surgical Company's key executives?
STAAR Surgical Company's management team includes the folowing people:
- Caren L. Mason, President, Chief Executive Officer, Director
- Deborah J. Andrews, Vice President, Interim Chief Financial Officer
- Hans-Martin Blickensdoerfer, Senior Vice President - Commercial Operations for Europe, Middle East, Africa, Latin America and China.
- James E. Francese, Senior Vice President of North American and APAC
- Keith Holliday Ph.D., Chief Technology Officer, Vice President
- William Walter Goodmen, Vice President - Global Human Resources
- Jon K. Hayashida, Vice President - Global Clinical and Medical Affairs
- Philippe Subrin, Vice President-ICL Manufacturing
- Samuel J. Gesten, Vice President - Business Development, Chief Legal Officer and Secretary
- Denise McEachern, Global Head of Regulatory Affairs and Quality Assurance
Who owns STAAR Surgical Company stock?
STAAR Surgical Company's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Broadwood Capital Inc. (26.41%), Palo Alto Investors LLC (8.58%), Vanguard Group Inc. (3.13%), State Street Corp (1.66%), Baillie Gifford & Co. (1.63%) and Northern Trust Corp (1.18%). Company insiders that own STAAR Surgical Company stock include Broadwood Partners Lp, Hans-Martin Blickensdoerfer and Richard A Meier. View Institutional Ownership Trends for STAAR Surgical Company.
Who sold STAAR Surgical Company stock? Who is selling STAAR Surgical Company stock?
STAAR Surgical Company's stock was sold by a variety of institutional investors in the last quarter, including Tiverton Asset Management LLC, Wells Fargo & Company MN, Trexquant Investment LP, GSA Capital Partners LLP, California State Teachers Retirement System, Williams Jones & Associates LLC, TIAA CREF Investment Management LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for STAAR Surgical Company.
Who bought STAAR Surgical Company stock? Who is buying STAAR Surgical Company stock?
STAAR Surgical Company's stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Candriam Luxembourg S.C.A., Palo Alto Investors LLC, State Street Corp, Lincoln National Corp, Campbell & CO Investment Adviser LLC, Northern Trust Corp and Susquehanna International Group LLP. View Insider Buying and Selling for STAAR Surgical Company.
How do I buy STAAR Surgical Company stock?
Shares of STAAR Surgical Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is STAAR Surgical Company's stock price today?
One share of STAAR Surgical Company stock can currently be purchased for approximately $10.90.
MarketBeat Community Rating for STAAR Surgical Company (NASDAQ STAA)MarketBeat's community ratings are surveys of what our community members think about STAAR Surgical Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for STAAR Surgical Company (NASDAQ:STAA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 1 Buy Rating |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $12.00 (10.09% upside) |
Analysts' Ratings History for STAAR Surgical Company (NASDAQ:STAA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/6/2017 | Canaccord Genuity | Reiterated Rating | Hold | $11.00 | Low |  |
| 8/14/2017 | Benchmark Co. | Boost Price Target | Buy -> Buy | $12.00 -> $13.00 | Medium | |
| 8/4/2016 | William Blair | Reiterated Rating | Market Perform | | N/A | |
| 5/12/2016 | Stephens | Downgrade | Overweight -> Equal Weight | | N/A | |
(Data available from 9/24/2015 forward)
Earnings History for STAAR Surgical Company (NASDAQ:STAA)Earnings History by Quarter for STAAR Surgical Company (NASDAQ STAA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/1/2017 | | ($0.04) | | | | | N/A | |
| 8/2/2017 | Q2 2017 | ($0.05) | ($0.01) | $22.15 million | $21.90 million | View | Listen | |
| 5/3/2017 | Q1 2017 | ($0.05) | ($0.05) | | $20.35 million | View | Listen | |
| 3/2/2017 | Q4 2016 | ($0.02) | $0.02 | $22.25 million | $22.10 million | View | Listen | |
| 11/3/2016 | Q316 | ($0.04) | ($0.02) | $20.70 million | $20.05 million | View | Listen | |
| 8/3/2016 | Q216 | ($0.05) | ($0.05) | $19.88 million | $21.00 million | View | Listen | |
| 5/11/2016 | Q116 | ($0.17) | ($0.01) | $19.60 million | $19.30 million | View | Listen | |
| 3/2/2016 | Q415 | ($0.02) | $0.01 | $19.11 million | $20.90 million | View | Listen | |
| 10/28/2015 | Q315 | ($0.04) | ($0.04) | $17.87 million | $18.80 million | View | Listen | |
| 4/29/2015 | Q115 | ($0.04) | $0.03 | $17.85 million | $18.90 million | View | Listen | |
| 2/25/2015 | Q414 | ($0.05) | ($0.03) | $16.60 million | $16.60 million | View | Listen | |
| 10/30/2014 | Q314 | $0.02 | ($0.04) | $19.53 million | $18.20 million | View | Listen | |
| 7/30/2014 | Q214 | $0.03 | $0.01 | $19.80 million | $20.05 million | View | Listen | |
| 4/28/2014 | Q114 | $0.01 | $0.04 | $19.44 million | $20.20 million | View | Listen | |
| 2/26/2014 | Q413 | $0.02 | $0.02 | $18.98 million | $18.90 million | View | Listen | |
| 10/30/2013 | Q313 | $0.02 | $0.04 | $17.35 million | $17.10 million | View | Listen | |
| 7/31/2013 | Q2 2013 | $0.04 | $0.05 | $17.40 million | $18.20 million | View | Listen | |
| 5/1/2013 | Q1 2013 | $0.04 | $0.08 | $17.27 million | $18.00 million | View | Listen | |
| 2/27/2013 | Q4 2012 | $0.03 | $0.01 | $17.55 million | $16.50 million | View | Listen | |
| 10/31/2012 | Q312 | $0.01 | $0.04 | $16.78 million | $15.90 million | View | N/A | |
| 8/1/2012 | | $0.03 | $0.03 | | | View | N/A | |
| 5/2/2012 | | $0.03 | $0.04 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for STAAR Surgical Company (NASDAQ:STAA)Current Year EPS Consensus Estimate: $-0.03 EPS
Next Year EPS Consensus Estimate: $0.19 EPS
Dividend History for STAAR Surgical Company (NASDAQ:STAA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for STAAR Surgical Company (NASDAQ:STAA)Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 76.54%
Insider Trades by Quarter for STAAR Surgical Company (NASDAQ:STAA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/9/2016 | Hans-Martin Blickensdoerfer | VP | Sell | 25,000 | $11.14 | $278,500.00 | |
| 6/29/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 14,144 | $5.24 | $74,114.56 | |
| 5/25/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 77,842 | $5.16 | $401,664.72 | |
| 5/24/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 70,000 | $5.16 | $361,200.00 | |
| 5/23/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 3,138 | $5.24 | $16,443.12 | |
| 5/20/2016 | Richard A Meier | Director | Sell | 25,000 | $5.35 | $133,750.00 | |
| 5/17/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 9,313 | $5.23 | $48,706.99 | |
| 5/16/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 336,210 | $5.49 | $1,845,792.90 | |
| 2/9/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 91,770 | $6.25 | $573,562.50 | |
| 2/3/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 121,599 | $6.40 | $778,233.60 | |
| 2/1/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 65,983 | $6.48 | $427,569.84 | |
| 1/27/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 239,013 | $6.63 | $1,584,656.19 | |
| 1/26/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 112,900 | $6.60 | $745,140.00 | |
| 1/25/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 81,752 | $6.74 | $551,008.48 | |
| 1/20/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 72,858 | $6.75 | $491,791.50 | |
| 1/15/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 135,725 | $6.73 | $913,429.25 | |
| 1/11/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 86,586 | $6.83 | $591,382.38 | |
| 1/7/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 267,047 | $6.95 | $1,855,976.65 | |
| 1/4/2016 | Broadwood Partners Lp | Major Shareholder | Buy | 165,461 | $7.11 | $1,176,427.71 | |
| 9/29/2015 | Broadwood Partners Lp | Major Shareholder | Buy | 311,099 | $7.08 | $2,202,580.92 | |
| 8/25/2015 | Broadwood Partners Lp | Major Shareholder | Buy | 188,881 | $7.17 | $1,354,276.77 | |
| 8/24/2015 | Caren L Mason | CEO | Buy | 10,000 | $7.34 | $73,400.00 | |
| 4/6/2015 | Samuel J Gesten | VP | Sell | 3,223 | $7.14 | $23,012.22 | |
| 3/3/2015 | Robin Hughes | VP | Sell | 23,253 | $15.82 | $367,862.46 | |
| 11/19/2014 | Broadwood Partners Lp | Major Shareholder | Buy | 189,646 | $8.64 | $1,638,541.44 | |
| 11/18/2014 | Broadwood Partners Lp | Major Shareholder | Buy | 39,400 | $8.67 | $341,598.00 | |
| 11/17/2014 | Broadwood Partners Lp | Major Shareholder | Buy | 118,200 | $8.63 | $1,020,066.00 | |
| 11/10/2014 | Broadwood Partners Lp | Major Shareholder | Buy | 500 | $8.79 | $4,395.00 | |
| 11/7/2014 | Broadwood Partners Lp | Major Shareholder | Buy | 80,000 | $8.92 | $713,600.00 | |
| 11/4/2014 | Broadwood Partners Lp | Major Shareholder | Buy | 260,341 | $9.20 | $2,395,137.20 | |
| 5/15/2014 | John Moore | Director | Sell | 2,800 | $14.87 | $41,636.00 | |
| 3/19/2014 | James Francese | VP | Sell | 16,666 | $17.22 | $286,988.52 | |
| 3/17/2014 | Robin Hughes | VP | Sell | 5,672 | $16.61 | $94,211.92 | |
| 9/4/2013 | Deborah Andrews | CFO | Sell | 50,000 | $12.88 | $644,000.00 | |
| 8/20/2013 | Deborah Andrews | CFO | Sell | 33,515 | $11.65 | $390,449.75 | |
| 8/12/2013 | Deborah Andrews | CFO | Sell | 9,079 | $11.62 | $105,497.98 | |
| 8/7/2013 | Deborah Andrews | CFO | Sell | 11,721 | $11.79 | $138,190.59 | |
| 5/9/2013 | Deborah J Andrews | CFO | Sell | 5,000 | $8.96 | $44,800.00 | |
| 12/11/2012 | John C Moore | Director | Buy | 5,000 | $5.46 | $27,300.00 | |
| 11/15/2012 | Broadwood Partners Lp | Major Shareholder | Buy | 2,618 | $5.00 | $13,090.00 | |
| 11/15/2012 | Mark B Logan | Director | Buy | 3,600 | $5.22 | $18,792.00 | |
| 11/14/2012 | Barry G Caldwell | CEO | Buy | 5,000 | $5.04 | $25,200.00 | |
| 11/2/2012 | Broadwood Partners Lp | Major Shareholder | Buy | 22,572 | $5.00 | $112,860.00 | |
| 8/9/2012 | Barry G Caldwell | CEO | Buy | 5,000 | $6.57 | $32,850.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for STAAR Surgical Company (NASDAQ:STAA)
Latest Headlines for STAAR Surgical Company (NASDAQ:STAA)
| Source: |
|
| Date | Headline |
|---|
 | ETFs with exposure to STAAR Surgical Co. : September 22, 2017
finance.yahoo.com - September 23 at 8:48 AM |
 | STAAR Surgical Company (STAA) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - September 23 at 7:26 AM |
| STAAR Surgical Company (STAA) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - September 22 at 6:24 AM |
| STAAR Surgical (STAA) & Bio-Rad Laboratories (BIO) Head-To-Head Contrast
www.americanbankingnews.com - September 16 at 4:42 AM |
| STAAR Surgical (STAA) & The Competition Head to Head Review
www.americanbankingnews.com - September 12 at 12:28 AM |
| STAAR Surgical Company (STAA) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - September 10 at 10:10 PM |
| InspireMD (NSPR) & STAAR Surgical (STAA) Head to Head Comparison
www.americanbankingnews.com - September 7 at 4:28 AM |
| BidaskClub Upgrades STAAR Surgical Company (STAA) to "Hold"
www.americanbankingnews.com - August 19 at 3:26 PM |
| TheStreet Upgrades STAAR Surgical Company (STAA) to C
www.americanbankingnews.com - August 17 at 12:26 PM |
| Corporate News Blog - STAAR Surgical Announces Strategic Cooperation Agreement with Seoul/Busan Eye Clinic
finance.yahoo.com - August 17 at 7:58 AM |
| STAAR Surgical and Seoul/Busan BalGeunSeSang Eye Clinic Announce Strategic Cooperation Agreement
finance.yahoo.com - August 15 at 7:22 AM |
| STAAR Surgical Company (NASDAQ:STAA) Price Target Raised to $13.00 at Benchmark Co.
www.americanbankingnews.com - August 14 at 8:36 AM |
| STAAR Surgical Company (STAA) Upgraded to Sell at BidaskClub
www.americanbankingnews.com - August 12 at 11:32 PM |
| Brokerages Set $11.67 Target Price for STAAR Surgical Company (STAA)
www.americanbankingnews.com - August 11 at 11:14 PM |
| STAAR Surgical (STAA) versus OraSure Technologies (OSUR) Head-To-Head Comparison
www.americanbankingnews.com - August 6 at 2:22 PM |
| STAAR Surgical Company (NASDAQ:STAA) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - August 3 at 9:21 PM |
| STAAR Surgical Company (NASDAQ:STAA) Price Target Increased to $11.00 by Analysts at Canaccord Genuity
www.americanbankingnews.com - August 3 at 6:06 PM |
 | STAAR's (STAA) CEO Caren Mason on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 3 at 7:34 AM |
 | EARNINGS SUMMARY: Details of STAAR Surgical Company Q2 Earnings Report
www.rttnews.com - August 3 at 7:34 AM |
| STAAR Surgical Reports Second Quarter 2017 Results
finance.yahoo.com - August 3 at 7:34 AM |
| Edited Transcript of STAA earnings conference call or presentation 2-Aug-17 8:30pm GMT
finance.yahoo.com - August 3 at 7:34 AM |
| Staar Surgical reports 2Q loss
finance.yahoo.com - August 3 at 7:34 AM |
| Critical Comparison: STAAR Surgical (STAA) versus OraSure Technologies (OSUR)
www.americanbankingnews.com - July 31 at 9:32 AM |
| STAAR Surgical Company (STAA) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 27 at 4:09 PM |
| STAAR Surgical to Report Second Quarter Results on August 2, 2017
finance.yahoo.com - July 20 at 8:08 AM |
| STAAR Surgical Company (STAA) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - July 5 at 11:00 AM |
| Zacks: STAAR Surgical Company (STAA) Given $12.00 Consensus Price Target by Brokerages
www.americanbankingnews.com - June 22 at 6:42 PM |
 | Staar Surgical to pay $7 million in investor suit over FDA violations
www.reuters.com - June 22 at 1:50 PM |
| STAAR Surgical Co. – Value Analysis (NASDAQ:STAA) : June 19, 2017
finance.yahoo.com - June 20 at 8:13 AM |
| STAAR Surgical Co. breached its 50 day moving average in a Bullish Manner : STAA-US : June 16, 2017
finance.yahoo.com - June 17 at 6:25 AM |
| Reviewing Inogen (INGN) and STAAR Surgical Company (STAA)
www.americanbankingnews.com - June 14 at 7:50 AM |
| STAAR Surgical Co. breached its 50 day moving average in a Bearish Manner : STAA-US : May 22, 2017
finance.yahoo.com - May 22 at 8:49 AM |
| STAAR Surgical Announces CE Mark Approval for the EVO+ Visian ICL with Aspheric (EDOF) Optic
finance.yahoo.com - May 11 at 9:57 PM |
| STAAR Surgical Co. breached its 50 day moving average in a Bearish Manner : STAA-US : May 10, 2017
finance.yahoo.com - May 10 at 10:34 AM |
| STAAR Surgical Company (STAA) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 9 at 11:00 AM |
| ETFs with exposure to STAAR Surgical Co. : May 8, 2017
finance.yahoo.com - May 8 at 7:32 PM |
| STAAR Surgical Company (STAA) Forecasted to Earn FY2017 Earnings of ($0.05) Per Share
www.americanbankingnews.com - May 8 at 9:38 AM |
| STAAR Surgical Co. :STAA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017
finance.yahoo.com - May 6 at 10:03 AM |
| STAAR Surgical Company (STAA) Announces Earnings Results
www.americanbankingnews.com - May 5 at 10:47 PM |
| STAAR Surgical Company Forecasted to Post FY2018 Earnings of $0.09 Per Share (STAA)
www.americanbankingnews.com - May 5 at 6:52 PM |
| Somewhat Favorable Media Coverage Very Likely to Affect STAAR Surgical Company (STAA) Stock Price
www.americanbankingnews.com - May 4 at 9:14 PM |
| Edited Transcript of STAA earnings conference call or presentation 3-May-17 8:30pm GMT
finance.yahoo.com - May 4 at 8:55 PM |
| EARNINGS SUMMARY: Details of STAAR Surgical Company Q1 Earnings Report
www.rttnews.com - May 3 at 6:12 PM |
| BRIEF-Staar Surgical reports Q1 sales $20.4 million
www.reuters.com - May 3 at 6:12 PM |
| STAAR Surgical Reports First Quarter 2017 Results
finance.yahoo.com - May 3 at 6:12 PM |
| Staar Surgical reports 1Q loss
finance.yahoo.com - May 3 at 6:12 PM |
| Investor Network: STAAR Surgical Company to Host Earnings Call
finance.yahoo.com - May 3 at 10:37 AM |
| Positive Media Coverage Somewhat Unlikely to Impact STAAR Surgical Company (STAA) Stock Price
www.americanbankingnews.com - April 29 at 10:47 PM |
| STAAR Surgical Co. – Value Analysis (NASDAQ:STAA) : April 27, 2017
finance.yahoo.com - April 27 at 8:24 PM |
| STAAR Surgical Co. breached its 50 day moving average in a Bullish Manner : STAA-US : April 26, 2017
finance.yahoo.com - April 26 at 9:09 AM |
STAAR Surgical Company (STAA) Chart for Sunday, September, 24, 2017
